Clinical Trial Update: ARQ 501 in Combination With Docetaxel in Patients With Cancer [Phase 1]

View source ↗

Summary

This clinical trial update reports the completion of a Phase 1 study evaluating the combination of ARQ 501 with docetaxel in patients with carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma

Drugs mentioned

• ARQ 501
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Conditions: Carcinoma | Phase 1 | Status: COMPLETED